Sickle Cell Disease: Diagnosis and Comprehensive Management
Hydroxyurea, crizanlizumab, VOC and acute chest syndrome treatment, exchange transfusion, gene therapy, and lifelong complication surveillance.
Sickle cell disease (SCD) is an autosomal recessive hemoglobinopathy caused by a single point mutation in the HBB gene (beta-globin Glu6Val), producing hemoglobin S that polymerizes when deoxygenated. This polymerization deforms erythrocytes into rigid sickle shapes that obstruct microvessels and hemolyze prematurely, generating the dual phenotype of vaso-occlusive crises (pain, organ infarction) and chronic hemolytic anemia (icterus, gallstones, pulmonary hypertension). Genotypes range in severity from severe HbSS and HbSβ⁰-thalassemia (75% of US patients) to milder HbSC and HbSβ⁺-thalassemia. Modern disease-modifying therapy rests on three pillars: hydroxyurea 15-35 mg/kg/day PO (induces fetal hemoglobin, halves VOC frequency, reduces mortality), L-glutamine L-glutamine 0.3 g/kg PO BID, and crizanlizumab Crizanlizumab 5 mg/kg IV monthly (P-selectin inhibitor; reduces VOC). Acute vaso-occlusive crisis is treated with prompt opioid analgesia, IV fluids at maintenance only (avoid overload), incentive spirometry, and oxygen if hypoxic. Acute chest syndrome (ACS) – the leading cause of mortality – mandates broad-spectrum antibiotics, transfusion, and exchange transfusion if Hb >9 or PaO2 <70%. Stroke prevention with annual transcranial Doppler in children age 2-16 and chronic transfusion if TCD >200 cm/s reduces primary stroke by 90%. Curative options have expanded with hematopoietic stem cell transplant from matched sibling donor (cure rate >90%) and FDA-approved gene therapies (exa-cel/Casgevy, lovo-cel/Lyfgenia, December 2023).
S1. Pathophysiology and Genotypes
Sickle cell disease arises from a single nucleotide substitution (GAG→GTG) in codon 6 of the HBB gene on chromosome 11, replacing glutamic acid with valine in the beta-globin chain. The hydrophobic valine creates a sticky surface on hemoglobin S (HbS) tetramers; in the deoxygenated state, this surface engages a complementary pocket on adjacent HbS tetramers, triggering polymerization into long fibers that distort the red cell into a crescent (sickle) shape. The polymerization is highly dependent on intracellular HbS concentration (third-power exponential), oxygen saturation, pH, and temperature. Sickled erythrocytes have decreased deformability, adhere abnormally to vascular endothelium via P-selectin, VCAM-1, and ICAM-4, and trigger neutrophil and platelet activation, generating microvascular occlusion and a chronic inflammatory state.
Sickled cells also have a markedly shortened life span (10-20 days vs. 120 days for normal RBCs), producing chronic hemolytic anemia with all its sequelae: gallstones from chronic bilirubin overload, pulmonary hypertension from nitric oxide scavenging by free hemoglobin, leg ulcers, priapism, and renal medullary necrosis. The two phenotypes (vaso-occlusion and hemolysis) coexist with variable predominance: HbSS shows both; HbSC has milder anemia but more retinopathy and avascular necrosis; sickle trait (HbAS) is generally asymptomatic but predisposes to splenic infarction at altitude, exertional rhabdomyolysis, and renal medullary carcinoma.
Sickle cell genotypes
| Genotype | Hb electrophoresis | Severity | Notes |
|---|---|---|---|
| HbSS (homozygous SS) | HbS >90%, HbF 1-15%, no HbA | Severe | ~65% of US SCD patients; full clinical phenotype |
| HbSβ⁰-thalassemia | HbS >80%, HbF 5-20%, no HbA | Severe (similar to SS) | ~10% of US SCD; manage like HbSS |
| HbSC | HbS ~50%, HbC ~50%, no HbA | Moderate | ~25% of US SCD; less anemia, more retinopathy & avascular necrosis |
| HbSβ⁺-thalassemia | HbS >60%, HbA 5-30%, HbF variable | Mild-moderate | Some HbA production; better baseline Hb |
| HbS-HPFH (high persistence HbF) | HbS 65-80%, HbF 20-30% | Mild/asymptomatic | Persistent fetal hemoglobin protective |
| HbAS (sickle trait) | HbA >55%, HbS 35-45% | Asymptomatic | Renal medullary CA, exertional risk, splenic infarction at altitude |
S2. Diagnosis and Newborn Screening
Newborn screening
Universal newborn screening for SCD is mandated in all 50 US states since 2006 (and routine in UK, France, Netherlands, Brazil). Screening uses isoelectric focusing or HPLC on dried blood spot. Confirmation with second sample is required for any positive screen. Early identification enables: (1) penicillin prophylaxis from 2 months of age (reduces pneumococcal mortality >80%), (2) pneumococcal conjugate vaccine, (3) parental education on splenic sequestration, (4) initiation of hydroxyurea by 9-12 months in HbSS, (5) annual transcranial Doppler from age 2.
Confirmatory testing
| Test | Purpose | Result in HbSS |
|---|---|---|
| Hemoglobin electrophoresis (HPLC, IEF) | Identify and quantify Hb variants | HbS >90%, HbF 1-15%, no HbA, HbA2 normal/elevated |
| Sickle solubility test (sodium dithionite) | Screening – turbidity if HbS present | Positive (does not distinguish trait vs disease) |
| Peripheral blood smear | Sickle cells, Howell-Jolly bodies (asplenia), polychromasia, target cells | Sickled cells, Howell-Jolly bodies after age 5 |
| CBC | Baseline Hb, MCV, reticulocyte count | Hb 6-9 g/dL, reticulocytes 5-15%, mild leukocytosis |
| Genetic testing (HBB sequencing) | Confirm specific mutation; genetic counseling | Homozygous Glu6Val (or compound heterozygote) |
| Family screening | Genetic counseling for parents and siblings | Both parents are at minimum HbAS |
Baseline laboratory and imaging at diagnosis
- CBC with differential, reticulocyte count, peripheral smear
- CMP (creatinine, AST/ALT, bilirubin, LDH)
- Hemoglobin electrophoresis (HPLC) with HbF quantification
- Iron studies, ferritin (baseline; rises with chronic transfusion)
- G6PD screen (some hydroxyurea concerns)
- HIV, HBV, HCV serology (transfusion safety baseline)
- Echocardiogram (annual after age 5; tricuspid regurgitant jet velocity to screen pulmonary HTN)
- Transcranial Doppler ultrasound (annual ages 2-16; STOP study indication for chronic transfusion if TAMV >200 cm/s)
- Pulmonary function tests, oxygen saturation, sleep study if symptoms
- Retinal exam annually from age 10 (especially HbSC for proliferative retinopathy)
S3. Disease-Modifying Therapy
Three FDA-approved disease-modifying agents
| Agent | Class / Mechanism | Dose | Year approved | Key trial |
|---|---|---|---|---|
| Hydroxyurea (Droxia, Siklos) | Ribonucleotide reductase inhibitor; induces HbF | 15-35 mg/kg/day PO (start 15, titrate to MTD) | 1998 | MSH (1995): 44% reduction in VOC, 50% mortality reduction |
| L-glutamine (Endari) | Antioxidant precursor (NAD+); reduces oxidative stress | L-glutamine 0.3 g/kg PO BID (max 30 g/day) | 2017 | Trial: 25% VOC reduction, 60% reduction in ACS |
| Crizanlizumab (Adakveo) | P-selectin monoclonal antibody (humanized IgG2) | Crizanlizumab 5 mg/kg IV q14d ×2 then q28d | 2019 | SUSTAIN: 45% reduction in VOC frequency vs placebo |
Hydroxyurea protocol (NHLBI 2014, updated 2024)
- All HbSS or HbSβ⁰ patients ≥9 months of age (regardless of severity)
- HbSC, HbSβ⁺-thalassemia: consider if recurrent VOC or ACS
- Starting dose: 15 mg/kg/day PO (round to nearest 500 mg capsule; 100 mg/mL liquid for infants)
- Pregnancy contraception advised; teratogenic in animals (Category D)
- Monthly CBC with differential and reticulocyte count for first 6 months, then q3 months
| Step | Action |
|---|---|
| Start | 15 mg/kg/day PO; CBC, reticulocyte count baseline |
| Titrate up | Increase by 5 mg/kg/day every 8 weeks if no toxicity, until myelosuppression |
| Target dose (MTD) | 20-35 mg/kg/day; MTD is highest dose without unacceptable myelosuppression |
| Hold for ANC <1.25 ×10⁹/L OR Plt <80 ×10⁹/L OR Hb <6 | Restart at 5 mg/kg lower when counts recover |
| Monitor response | HbF rise, MCV rise, fewer VOC; expected 4-6 month delay for full effect |
| Side effects | Cytopenias (most common), nail/skin hyperpigmentation, fatigue, leg ulcers; long-term cancer risk not increased in registry data |
S4. Acute Crises: VOC, ACS, Stroke, Sepsis
Vaso-occlusive crisis (VOC) – the most common SCD presentation
| Time | Action |
|---|---|
| 0-30 min (triage) | Pain assessment (0-10), vitals, peripheral oxygen saturation, focused history (typical pain pattern? trigger? home meds?) |
| 0-30 min (initial analgesia) | Goal: opioid within 30 min of arrival. Morphine 0.1-0.15 mg/kg IV or hydromorphone 0.015-0.02 mg/kg IV; reassess q15-30 min, repeat to effect |
| 0-60 min | IV fluids at MAINTENANCE rate only (D5 1/2 NS at maintenance). Avoid bolus or aggressive hydration – precipitates ACS via pulmonary edema. Incentive spirometry q2h while awake. |
| 0-2 h | CBC, reticulocyte count, CMP, type and screen, urinalysis. Chest x-ray if any respiratory complaint, fever, or chest pain. Transition to PCA if ongoing pain (basal + bolus). |
| 2-24 h | NSAIDs (ketorolac 15-30 mg IV q6h × 5 days max) for synergistic analgesia if no contraindication. DVT prophylaxis with SCD-specific protocol. Maintain SpO2 >95% (oxygen only if hypoxic). |
| Discharge | Wean opioids; outpatient pain plan; review hydroxyurea adherence; follow-up within 1 week; address triggers (cold, dehydration, infection, stress) |
Acute chest syndrome (ACS) – the leading cause of SCD mortality
- New pulmonary infiltrate on chest X-ray (≥1 segment, not atelectasis)
- Plus at least ONE of: fever >38.5°C, hypoxia (SpO2 <95% or 4% drop from baseline), tachypnea, cough, chest pain, wheezing, retractions
- Most common etiologies: infection (Mycoplasma, Chlamydophila, viral, bacterial), fat embolism from bone marrow infarction, opioid-induced hypoventilation/atelectasis, in situ pulmonary microthrombosis
| Treatment component | Specifics |
|---|---|
| Antibiotics | Ceftriaxone 1-2 g IV daily + azithromycin 500 mg IV/PO daily (atypical coverage essential); add vancomycin if severe |
| Transfusion | Simple transfusion if Hb <9 g/dL (1-2 units to raise Hb to 10); EXCHANGE transfusion if Hb >9 g/dL OR PaO2 <70 mmHg OR rapid clinical decline. Goal: HbS <30% post-exchange. |
| Oxygen | Maintain SpO2 ≥95%; high-flow nasal cannula or NIV if increased work of breathing; intubation if respiratory failure |
| Bronchodilators | Albuterol 2.5 mg nebulized q4h if wheezing or asthma history (asthma comorbidity 30%) |
| DVT prophylaxis | Prophylactic enoxaparin (no contraindications); ambulation as tolerated |
| Bronchoscopy | Consider if no improvement after 48 h, especially to identify atypical infection or fat embolism |
| Steroids | NOT routinely recommended in SCD-ACS (rebound VOC risk); reserve for severe asthma exacerbation |
Acute ischemic stroke and silent cerebral infarction
- Emergency exchange transfusion within 4-6 hours, target HbS <30%
- Brain MRI/MRA preferred (catheter angiography risky from contrast nephropathy + sickling)
- tPA NOT routinely used in pediatric SCD stroke (use exchange transfusion); adult SCD stroke – tPA can be considered if Hb >10 after transfusion
- Ongoing chronic transfusion therapy (target HbS <30%) for life or until HSCT
- Recurrence risk without secondary prevention: 50-70% within 3 years
Stroke primary prevention – STOP study (children only)
- Annual transcranial Doppler in HbSS children ages 2-16; measure time-averaged maximum velocity (TAMV) in MCA
- If TAMV >200 cm/s (high risk): chronic transfusion therapy; reduces stroke from 11% per year to 1% per year
- Continue chronic transfusion until at least age 18 or transition to hydroxyurea (TWiTCH trial: hydroxyurea non-inferior to transfusion for stroke prevention IF stable on transfusion ≥1 year)
- Adults: TCD not validated; brain MRI for silent infarct screening, no consensus on chronic transfusion
Sepsis and infection management
- Blood cultures, urine culture, chest x-ray, CBC, CMP
- Empiric broad-spectrum antibiotics within 1 hour: Ceftriaxone 50-75 mg/kg IV (max 2g) for outpatient assessment; add vancomycin if hospitalized or septic appearing
- Admit if temp >39.5°C, age <5, ill-appearing, WBC >30 or <5, Hb >2 g/dL below baseline, dehydrated, or unable to follow up
- Continue penicillin VK 125-250 mg PO BID prophylaxis from age 2 months to at least age 5 (some recommend lifelong)
Vaccinations (mandatory)
- Pneumococcal conjugate (PCV13/15/20) per ACIP schedule
- Pneumococcal polysaccharide (PPSV23) at age 2 and revaccinate at age 7
- Meningococcal conjugate (MenACWY) at age 2 and booster q5 years; MenB age 10+
- Haemophilus influenzae type b (Hib) per pediatric schedule
- Annual influenza
- COVID-19 per CDC guidance (high-risk)
- Hepatitis B (chronic transfusion exposure)
S5. Chronic Complications and Curative Therapy
Chronic complications by organ system
| System | Complication | Surveillance / Management |
|---|---|---|
| Pulmonary | Pulmonary hypertension (10-30%), chronic restrictive lung disease, asthma, sleep apnea | Annual TR jet velocity (>2.5 m/s = high mortality); right heart cath if elevated; PFTs; sleep study if snoring/somnolence; PHTN treated with hydroxyurea optimization, transfusion, possibly bosentan/sildenafil (controversial in SCD) |
| Cardiac | Cardiomegaly, diastolic dysfunction, MI from coronary microvessel occlusion | Annual echo, ECG; cardiac MRI for iron overload (chronic transfusion); standard CV risk factor management |
| Renal | Hyposthenuria (universal), papillary necrosis, FSGS, CKD, ESRD; renal medullary CA (rare) | Annual UA, microalbumin, creatinine; ACE inhibitor for proteinuria; avoid NSAIDs in CKD; transplant outcomes good |
| Hepatobiliary | Cholelithiasis (60-90% by adulthood), iron overload from transfusions, hepatic sequestration | RUQ ultrasound q2 years; cholecystectomy if symptomatic; ferritin q3 months on chronic transfusion; chelation if ferritin >1000 (deferasirox 14-28 mg/kg/day, deferoxamine, deferiprone) |
| Musculoskeletal | Avascular necrosis (femoral > humeral head; 30-50% lifetime), dactylitis, osteomyelitis (Salmonella classic) | MRI for AVN if hip/shoulder pain; core decompression early; arthroplasty for severe AVN; bone biopsy for osteo |
| Ophthalmologic | Proliferative retinopathy (HbSC > SS), vitreous hemorrhage, retinal detachment | Annual dilated retinal exam from age 10; laser photocoagulation for proliferative changes |
| Genitourinary | Priapism (35% lifetime), erectile dysfunction | Acute >4h: aspiration + intracavernous phenylephrine; chronic: hydroxyurea, exchange transfusion if severe |
| Neurologic | Silent cerebral infarcts (37% by age 14), cognitive impairment, seizures, moyamoya syndrome | Brain MRI screening at age 5 and adolescence; school accommodations; chronic transfusion if extensive silent infarcts |
| Dermatologic | Leg ulcers (especially malleolar; 5-10%), poor wound healing | Compression, wound care, topical steroids; transfusion in refractory cases |
| Endocrine | Delayed puberty, hypogonadism (transfusion-related), diabetes (iron overload), growth retardation | Tanner staging, IGF-1, sex hormones, A1c; testosterone/estrogen replacement if hypogonadal |
| Psychosocial | Depression, chronic pain syndrome, school/employment difficulties | Routine screening, integrated psychology and social work; pain psychology referral |
Curative therapy
| Modality | Eligibility | Outcomes | Risks |
|---|---|---|---|
| Allogeneic HSCT (matched sibling) | Children with stroke, recurrent ACS, recurrent VOC; HLA-matched sibling donor; ideally before age 16 | Cure rate >90% in children, ~85% adults; event-free survival 84-90% | GVHD 10-20%, infertility, infection during conditioning; mortality 5-10% |
| Haploidentical HSCT | Patients without matched sibling; expanded with post-transplant cyclophosphamide protocols | Cure rate 70-85%; growing experience | Higher GVHD, graft failure rates than matched sibling |
| Exa-cel (Casgevy) – CRISPR-Cas9 gene editing | FDA approved Dec 2023 for HbSS age ≥12 with recurrent VOC | Phase 3: 97% (28/29) free of severe VOC at 12 months; HbF rises to 35-50% | Conditioning toxicity (busulfan), infertility, secondary malignancy theoretical, ~$2.2M cost |
| Lovo-cel (Lyfgenia) – lentiviral anti-sickling beta-globin | FDA approved Dec 2023 for HbSS age ≥12 with recurrent VOC | Phase 3: ~88% achieved complete VOC resolution; HbA-T87Q production | Conditioning toxicity, AML/MDS reported (BBC class warning), ~$3.1M cost |
| Chronic transfusion | Stroke prevention/secondary prevention, recurrent ACS, severe disease not amenable to other modifiers | Reduces sickling-related complications; goal HbS <30% | Iron overload (mandatory chelation), alloimmunization (~30%), infection, venous access |
- Hematology: All confirmed SCD; consider co-management with primary care; for hydroxyurea initiation, transfusion decisions, severe complication management
- Comprehensive SCD Center: All children at diagnosis; adults with severe phenotype; transition planning age 17-21; pre-conception counseling
- Transplant center: Children/young adults with stroke, recurrent ACS, recurrent VOC despite hydroxyurea, AVN; matched sibling donor or eligible for haploidentical/gene therapy
- Pulmonology: Suspected pulmonary HTN (TR jet >2.5 m/s), recurrent ACS, sleep apnea, restrictive lung disease
- Cardiology: Cardiomegaly on echo, arrhythmia, suspected MI, transfusion-related iron cardiomyopathy
- Nephrology: Persistent proteinuria (>300 mg/day), CKD stage 3+, ESRD planning
- Pain medicine: Refractory chronic pain, opioid management, multimodal pain plan
- Maternal-fetal medicine: All pregnant SCD patients (high-risk pregnancy: pre-eclampsia, ACS, VOC, fetal growth restriction)
- Genetic counseling: Diagnosis confirmation, family screening, pre-conception, prenatal diagnosis options
S7. Practice Insights: Bedside Notes on Sickle Cell Disease
(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)Sickle cell disease is largely managed in emergency departments, where a high opioid requirement still reads as drug-seeking and a drifting oxygen saturation goes unwatched, so this disease’s modern challenge is recognizing acute chest syndrome early enough to intervene and committing to disease-modifying therapy rather than just treating crises reactively. In experienced hands the pivot points are aggressive ACS recognition with low threshold for transfusion, hydroxyurea optimization to maximum tolerated dose, and patient advocacy because ED teams systematically under-treat sickle cell pain. Experienced practice tracks three things every clinic: VOC frequency, HbF percentage on hydroxyurea, and oxygen saturation trend (silent desaturation is concerning).
What the Guideline Misses — Pain Is Under-Treated in SCD
SCD patients are systematically under-dosed for opioids in ED settings — bias and unfounded “drug-seeking” concerns. In experienced practice every VOC patient gets aggressive multimodal pain management: IV opioids within 30 minutes of presentation, PCA pump for inpatient, scheduled NSAIDs (ketorolac, if renal function permits) + acetaminophen + warm packs. The 30-minute “door-to-analgesic” metric exists for a reason. Experienced practice writes pain protocols into outpatient discharge papers for emergency use.
Patterns Experienced Clinicians Have Seen Repeat — ACS Hides in Chest Pain
Acute chest syndrome (new pulmonary infiltrate + fever or respiratory symptoms) is the leading cause of adult SCD death. In published series, any SCD patient with chest pain, dyspnea, or hypoxia gets CXR + ABG + blood cultures within 1 hour. If new infiltrate appears, simple transfusion or exchange transfusion (depending on severity, baseline Hb, HbS%) plus broad-spectrum antibiotics + incentive spirometry q1h while awake + scheduled bronchodilators. Don’t wait for “worse” before transfusing.
Hydroxyurea Optimization Strategy
Hydroxyurea is the single most disease-modifying intervention for adult SCD — reduces VOC by ~50%, ACS by similar margin, mortality benefit demonstrated. Experienced clinicians titrate hydroxyurea to maximum tolerated dose: start 15-20 mg/kg/day, increase by 5 mg/kg every 8 weeks until MCV rises to 100-110, ANC nadirs to 2.0-3.0, target HbF 20-30%. About 30% of the patients are sub-optimally dosed at referral; meaningful dose escalation usually transforms their course.
Bedside Heuristic — Gene Therapy Conversation Early
Exa-cel (CRISPR) and lovo-cel (lentivirus-based) FDA approval in 2023 changed everything. In experienced practice every SCD patient under 50 with severe phenotype (3+ VOCs/year despite hydroxyurea, prior stroke, prior ACS) gets gene therapy or HSCT referral conversation early — not after they have failed everything. Cost, access, and conditioning toxicity are real barriers but the cure offer is real for the first time.
A Case That Reframed the established Approach — ACS Caught at Bedside Auscultation
A man in his late 30s with HbSS presented with VOC pain, started on PCA opioid + IV fluids. Day 3 of admission he reported “slight chest tightness” — no fever, SpO2 95% on room air, no obvious distress. Bedside auscultation revealed new fine crackles at left lower base. STAT CXR showed new left lower lobe infiltrate. ABG: pH 7.42, PaO2 75 (calculated A-a gradient 22). Started piperacillin-tazobactam + azithromycin, exchange transfusion targeting HbS <30%. By 24 hours after transfusion his oxygenation improved meaningfully, infiltrate stabilized, recovered without ICU transfer. What experienced clinicians learned: ACS in SCD patients hospitalized for VOC develops insidiously — daily auscultation + daily CXR threshold should be low. Experienced practice now auscultates every SCD VOC inpatient daily; the small physical exam catch prevented a likely ICU admission.
Practice Pattern Refinements That Diverge From Standard Guidelines
- Door-to-analgesic <30 minutes for every VOC presentation. Document this metric in patient pain plans they hand to ED staff. Seasoned clinicians provide a wallet card listing typical opioid doses, allergies, and home regimens. The bias against SCD patients is real; patient self-advocacy + clinician written orders cut through it.
- Hydroxyurea titration to maximum tolerated dose with HbF target 20-30%. Sub-optimal hydroxyurea is the most common preventable harm experienced practitioners see in adult SCD. Slow escalation by 5 mg/kg every 8 weeks until myelosuppression limits. Track MCV (should rise) and HbF (should rise) as response markers. the patients on optimized hydroxyurea have far fewer ED visits.
- Annual screening battery: TCD (children <16), echo (TRV for PH), retina exam, hip MRI (AVN screen if pain), TSH, vitamin D. Don’t wait for symptoms. Pulmonary hypertension (TRV ≥2.5 m/s) screen → confirmatory RHC if positive. AVN of femoral head is common and disabling — early detection allows core decompression in selected.
- Gene therapy/HSCT conversation at year 1 of severe phenotype, not “after all else fails.” Center the cure question early. The conditioning regimen for exa-cel takes months; insurance battles take longer. Patients should know about cure options when they are still healthy enough to be candidates, not in extremis.
S6. Pearls, Pitfalls, FAQ
FAQ
- Sickle Cell Vaso-Occlusive Crisis: ED Management and Pain Control
- Cold Agglutinin Disease & Cold AIHA: IgM Hemolysis Workup, Rituximab & Sutimlimab
- Paroxysmal Nocturnal Hemoglobinuria: Diagnosis, Eculizumab, and Pegcetacoplan
- Essential Thrombocythemia: Diagnosis and Management
- Marginal Zone Lymphoma: MALT, Splenic, and Nodal Subtypes — Diagnosis and Management
- Thalassemia Alpha and Beta: Genetic Basis, Diagnosis, and Transfusion-Iron Chelation Management